HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
25 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
DNAJB1
DnaJ heat shock protein family (Hsp40) member B1
Chromosome 19 · 19p13.12
NCBI Gene: 3337Ensembl: ENSG00000132002.10HGNC: HGNC:5270UniProt: P25685
267PubMed Papers
20Diseases
0Drugs
0Pathogenic Variants
FUNCTIONAL ROLE
Hub Gene
RESEARCH IMPACT
Trending
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
ATPase activator activitytranscription corepressor activityprotein bindingHsp70 protein bindingFibrolamellar Carcinomahepatocellular adenomabile duct adenocarcinomajaw disease
✦AI Summary

DNAJB1 is an HSP40 co-chaperone that functions as a critical regulator of cellular protein homeostasis and heat shock response. Mechanistically, DNAJB1 interacts with HSP70 to stimulate its ATPase activity and facilitate protein folding of unfolded substrates 12. The protein negatively regulates heat shock-induced HSF1 transcriptional activity during heat shock recovery 3. Beyond canonical chaperone functions, DNAJB1 plays specialized roles in protein quality control: it specifically recognizes oligomeric α-synuclein and recruits multiple HSP70 molecules to amyloid fibrils, enabling their disaggregation through coordinated entropic pulling forces—a mechanism relevant to Parkinson's disease pathology 4. Additionally, DNAJB1 differentially modulates phase separation of disease-related proteins like TDP-43, with effects varying by co-chaperone type 5. Clinically, DNAJB1 gained prominence through its fusion with PRKACA in fibrolamellar hepatocellular carcinoma (FLC), a rare but aggressive liver cancer. The DNAJB1-PRKACA fusion drives FLC through elevated PKA activity and impaired SIK signaling, leading to CRTC2/p300-mediated transcriptional reprogramming 6. Notably, the oncogenic phenotype depends on elevated PKA activity rather than the DNAJB1 domain itself 7. The fusion also disrupts cAMP compartmentation by blocking regulatory subunit phase separation 8. DNAJB1-PRKACA-derived peptides induce durable anti-tumor T cell responses, supporting peptide-based immunotherapy approaches 9. Related PRKACA/B fusions in pancreatobiliary tumors similarly drive oncocytic neoplasm development 10.

Sources cited
1
The protein negatively regulates heat shock-induced HSF1 transcriptional activity during heat shock recovery .
PMID: 9499401
2
Beyond canonical chaperone functions, DNAJB1 plays specialized roles in protein quality control: it specifically recognizes oligomeric α-synuclein and recruits multiple HSP70 molecules to amyloid fibrils, enabling their disaggregation through coordinated entropic pulling forces—a mechanism relevant to Parkinson's disease pathology .
PMID: 33177717
3
Additionally, DNAJB1 differentially modulates phase separation of disease-related proteins like TDP-43, with effects varying by co-chaperone type .
PMID: 36709343
4
The DNAJB1-PRKACA fusion drives FLC through elevated PKA activity and impaired SIK signaling, leading to CRTC2/p300-mediated transcriptional reprogramming .
PMID: 39326063
5
Notably, the oncogenic phenotype depends on elevated PKA activity rather than the DNAJB1 domain itself .
PMID: 38888469
6
The fusion also disrupts cAMP compartmentation by blocking regulatory subunit phase separation .
PMID: 32846158
7
DNAJB1-PRKACA-derived peptides induce durable anti-tumor T cell responses, supporting peptide-based immunotherapy approaches .
PMID: 36302754
8
Related PRKACA/B fusions in pancreatobiliary tumors similarly drive oncocytic neoplasm development .
PMID: 37871652
Disease Associationsⓘ20
Fibrolamellar CarcinomaOpen Targets
0.38Weak
bile duct adenocarcinomaOpen Targets
0.37Weak
hepatocellular adenomaOpen Targets
0.37Weak
jaw diseaseOpen Targets
0.31Weak
hepatocellular carcinomaOpen Targets
0.29Weak
HepatoblastomaOpen Targets
0.28Weak
smoking initiationOpen Targets
0.26Weak
risk-taking behaviourOpen Targets
0.25Weak
acute myeloid leukemiaOpen Targets
0.19Weak
non-small cell lung carcinomaOpen Targets
0.19Weak
skin squamous cell carcinomaOpen Targets
0.19Weak
esophageal squamous cell carcinomaOpen Targets
0.19Weak
melanomaOpen Targets
0.19Weak
oral squamous cell carcinomaOpen Targets
0.19Weak
lung adenocarcinomaOpen Targets
0.19Weak
head and neck squamous cell carcinomaOpen Targets
0.19Weak
breast carcinomaOpen Targets
0.19Weak
bladder transitional cell carcinomaOpen Targets
0.19Weak
chronic lymphocytic leukemiaOpen Targets
0.19Weak
urinary bladder carcinomaOpen Targets
0.19Weak
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Related Genes
BAG2Protein interaction100%GRPEL1Protein interaction100%MAPKAPK5Protein interaction100%HSPB8Protein interaction99%HSPA1LProtein interaction98%HSPB2Protein interaction98%
Tissue Expression6 tissues
Bone Marrow
100%
Liver
90%
Brain
50%
Lung
48%
Ovary
40%
Heart
36%
Gene Interaction Network
Click a node to explore
DNAJB1BAG2GRPEL1MAPKAPK5HSPB8HSPA1LHSPB2
PROTEIN STRUCTURE
Preparing viewer…
PDB3AGX · 1.85 Å · X-ray
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
0.95LoF Tolerant
pLIⓘ
0.00Tolerant
Observed/Expected LoF0.61 [0.40–0.95]
RankingsWhere DNAJB1 stands among ~20K protein-coding genes
  • #1,395of 20,598
    Most Researched267 · top 10%
  • #8,926of 17,882
    Most Constrained (LOEUF)0.95
Genes detectedDNAJB1
Sources retrieved25 papers
Response time—
📄 Sources
25▼
1
The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma.
PMID: 36302754
Nat Commun · 2022
1.00
2
Liver cancer multiomics reveals diverse protein kinase A disruptions convergently produce fibrolamellar hepatocellular carcinoma.
PMID: 39738196
Nat Commun · 2024
0.90
3
Molecular dissection of amyloid disaggregation by human HSP70.
PMID: 33177717
Nature · 2020
0.80
4
DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming.
PMID: 39326063
Cancer Discov · 2025
0.70
5
MARCO
PMID: 41274349
J Hepatol · 2025
0.68